Walter and Eliza Hall Institute of Medical Research, Melbourne 3051, Australia; Department of Medical Biology, University of Melbourne, Melbourne 3052, Australia.
Walter and Eliza Hall Institute of Medical Research, Melbourne 3051, Australia.
Cell. 2016 Oct 20;167(3):610-624. doi: 10.1016/j.cell.2016.07.055.
Malaria has been a major global health problem of humans through history and is a leading cause of death and disease across many tropical and subtropical countries. Over the last fifteen years renewed efforts at control have reduced the prevalence of malaria by over half, raising the prospect that elimination and perhaps eradication may be a long-term possibility. Achievement of this goal requires the development of new tools including novel antimalarial drugs and more efficacious vaccines as well as an increased understanding of the disease and biology of the parasite. This has catalyzed a major effort resulting in development and regulatory approval of the first vaccine against malaria (RTS,S/AS01) as well as identification of novel drug targets and antimalarial compounds, some of which are in human clinical trials.
疟疾一直是人类历史上的一个重大全球健康问题,也是许多热带和亚热带国家死亡和疾病的主要原因。在过去的十五年中,新的控制措施已将疟疾的发病率降低了一半以上,这使得消除疟疾甚至可能成为一种长期的可能性。要实现这一目标,需要开发新的工具,包括新型抗疟药物和更有效的疫苗,以及更深入地了解疾病和寄生虫的生物学特性。这促使人们进行了重大努力,最终开发出了第一种针对疟疾的疫苗(RTS,S/AS01)并获得了监管批准,同时还确定了新的药物靶点和抗疟化合物,其中一些已进入人体临床试验。